Navigation Links
Olympus Biotech International Ltd and BonAlive Biomaterials Ltd Announce Distribution Agreement
Date:1/20/2013

TURKU, Finland and LIMERICK, Ireland, January 21, 2013 /PRNewswire/ --

BonAlive Biomaterials Ltd, a manufacturer of implantable medical devices and an emerging leader in indications involving the treatment of chronically infected bone, and Olympus Biotech International Ltd, a wholly owned company of Olympus Corporation focused on minimally-invasive regenerative therapies in bone and soft tissues, today announced the signing of a multi-year exclusive distribution agreement. Under the agreement, Olympus Biotech International will have exclusive distribution rights for the BonAlive® granules product line in Germany, France and the UK. The product line covers regenerative products for orthopaedic and trauma surgeries.

     (Logo: http://photos.prnewswire.com/prnh/20130121/589026-a)

     (Logo: http://photos.prnewswire.com/prnh/20130121/589026-b)

The agreement is an important milestone in the commercialization strategy of the BonAlive® granules product line in the pathway of further expanding the access to hospitals in the large European markets.

"This newly established partnership enables us to work together with one of the most prominent leaders in the field of regenerative medicine in providing a complete portfolio of bone regeneration products to the community of orthopaedic and trauma surgeons" said Dr. Fredrik Ollila , CEO of BonAlive Biomaterials Ltd. "The establishment of a complete product offering will generate value and bring new opportunities in treatment of chronically infected bone".

"The cooperation and agreement with BonAlive Biomaterials Ltd completes our bone regeneration portfolio now also in the treatment of fractures and non-unions in patients with chronic infections. During our thorough global assessment of different technologies and options we were impressed by the clinical evidence and clinical data available for BonAlive®. We are very much convinced to have decided for a partnership with the company having the right approach to improve patient outcome" said Florian Kemmerich , President of Olympus Biotech International.

For more information about BonAlive Biomaterials Ltd, please visit http://www.bonalive.com

For more information about Olympus Biotech, visit http://www.olympusbiotech.com

About BonAlive Biomaterials Ltd

BonAlive Biomaterials Ltd is an emerging leader in the field of implantable medical devices for bone regeneration. The focus is to provide world-leading biomaterial solutions for the treatment of chronically infected bone. BonAlive® products are available in Europe, Middle East, Asia-Pacific, Africa, Brazil and the USA through a professional distributor network. The clinical use of BonAlive® is supported by a twenty year research history including several randomized prospective trials in the field of spine, benign bone tumor and trauma surgery. More than fifty peer reviewed articles have been published about BonAlive®.

About Olympus Biotech International Limited

Olympus Biotech was established in December, 2010 as a wholly owned company of Olympus Corporation. The vision of Olympus Biotech is to improve the patient Quality of Life by developing and distributing Regenerative Medicine that stimulates the intrinsic healing capacity in the living body. Olympus Biotech provides minimally-invasive regenerative therapies for bone and soft tissue including growth factors, scaffolds and cell harvesting technologies as well as tools for access, placement and delivery.

For questions or additional information, please contact:

Olympus Biotech International Limited
Dirk Dembski
Vice President Marketing and Business Development
Olympus Biotech International  
Mobile +49-172-2492700
dirk.dembski@olympusbiotech.com

BonAlive Biomaterials Ltd:
Fredrik Ollila , PhD
Chief Executive Officer
BonAlive Biomaterials Ltd
Mobile +358(0)400-931-209
Fax +358(0)421-917-744-00
fredrik.ollila@bonalive.com



'/>"/>
SOURCE BonAlive Biomaterials Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Olympus Introduces the Worlds First and Only Monopolar, Disposable Tonsil Adenoid Debrider (DTAD)
2. PROLOR Biotech To Present Preclinical Data On Its Long-Acting Clotting Factor Vlla At 2012 ASH Annual Meeting
3. XBiotech Reports Positive Phase II Interim Analysis Results in Vascular Disease
4. TNI BioTech, Inc. Signs Exclusive Distributor Agreement for Federal Republic of Nigeria with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC
5. Medical Marijuana Inc. Portfolio Company CanChew BioTechnologies Inc. Announces Final Three Days for Market Survey and Free Product Trial Registration
6. Cytos Biotechnology Ltd Reports Third Quarter 2012 Financial Results, Recent Development and Outlook
7. RayBiotech, Inc. and Abeome Corporation Announce an Agreement Related to Novel Research Products for Ovarian Cancer
8. XBiotech Reports Positive Phase II Interim Analysis Results From Type 2 Diabetes Study
9. Goodwin Biotechnology is a Three-Category Winner in the 2012 CMO Leadership Awards
10. Mersana Therapeutics Named a "Fierce 15" Biotech Company for 2012
11. Lifeline Biotechnologies Receives Third Software Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the ... Strategies" report to their offering. ... Pain Management in the ... their physical pain, emphasizing consumer survey analysis, including trends over ... adults who have selected illnesses/conditions strongly associated with physical pain ...
(Date:3/24/2017)... 24, 2017 ShangPharma, a leading ... cost-effective drug development and discovery services, technology, ... industry, announced today the intent for a ... be consolidating the Contract Research Organizations (CRO) ... ChemPartner. These entities include ChemPartner Shanghai, ChemPartner ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a ... Merck & Co., Inc., Biogen and Sanofi are involved in the development ... of which one is in Phase III stage, 15 are in Phase ...
Breaking Medicine Technology:
(Date:3/24/2017)... , ... March 24, 2017 , ... ... Society (ONS) wanted to create a communications platform that positions them as the ... Elliance and ONS reinvented their online publication as an always-on, always-fresh news, views ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro ... their partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is ... Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation ... and college Bible teacher residing in North Carolina with his wife, Anna Marie. He ... them with six grandchildren. David is also the author of “Shadow and Substance.” , ...
(Date:3/23/2017)... ... 2017 , ... The physicians of KSF Orthopaedic Center PA are proud to ... location is located at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 ... provide patients living in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The MBI “Hall of Fame” recognizes the ... acts have had a significant impact on the careers of all others involved. ... Inc. was inducted into the MBI’s Hall of Fame. The induction took place during ...
Breaking Medicine News(10 mins):